Sales and Marketing

Showing 15 posts of 11454 posts found.

Oncimmune Holdings sells businesses to Freenome in £13m deal

May 22, 2023 Sales and Marketing Freenome, Oncimmune Holdings, Oncology, acquisition

UK-based life sciences and immunodiagnostics firm Oncimmune Holdings has announced that it has sold its Oncimmune Limited and Oncimmune Europe …

Nido Biosciences raises $109m in funding for neurological diseases treatments

May 16, 2023 Sales and Marketing Financing, Neurology, Nido Biosciences, funding, neurology

US-based clinical-stage company Nido Biosciences has announced that is has received $109m in Seed, Series A and Series B financings, …

uniQure announces sale of royalty interest in Hemgenix for up to $400m

May 16, 2023 Sales and Marketing Haematology, Hemgenix, haemophilia, royalties, uniQure

uniQure has announced that it has entered a definitive agreement to sell a portion of the royalty rights due to …

Angelini Pharma and JCR Pharmaceuticals partner to develop new epilepsy therapies

May 12, 2023 Sales and Marketing Angelini Pharma, JCR Pharmaceuticals, Neurology, epilepsy

Angelini Pharma and JCR Pharmaceuticals have announced that they have entered into an exclusive global development and commercialisation agreement for …

Gilead acquires XinThera to strengthen pipeline in oncology and inflammation

May 10, 2023 Sales and Marketing Gilead, Oncology, XinThera, inflammation, oncology

Gilead Sciences has announced the acquisition of all outstanding shares of XinThera, a privately-owned biotech company based in San Diego, …

Maze Therapeutics and Sanofi sign exclusive worldwide license agreement for Pompe disease treatment

May 3, 2023 Sales and Marketing License Agreement, Pompe disease, Rare Diseases, Sanofi, maze therapeutics, treatment

Maze Therapeutics and Sanofi have announced that they have signed an exclusive worldwide license agreement for Maze’s gluogen synthase 1 …

FDA approves Pfizer’s pneumococcal conjugate vaccine for infants and children

April 28, 2023 Market Access, Research and Development, Sales and Marketing Ear Nose & throat, FDA, Immunology, Pfizer, Vaccine, pneumococcal vaccine

Pfizer has announced that the US Food and Drug Administration (FDA) has approved its PREVNAR 20 (20-valent pneumococcal conjugate vaccine) …

PANTHERx Rare announces release of treatment for rare stable Wilson Disease

April 20, 2023 Sales and Marketing

US-based rare medicines pharmacy PANTHERx Rare has announced the launch of Cuvrior, a treatment for stable Wilson Disease in adults …

Acadia Pharmaceuticals announces commercialisation of Daybue for Rett syndrome

April 19, 2023 Sales and Marketing

Acadia Pharmaceuticals has announced that Daybue (trofinetide) is now available for adult and paediatric patients over the age of two …

Ariceum Therapeutics announces extension of Series A financing for radiopharmaceutical clinical pipeline

April 18, 2023 Sales and Marketing

Private biotech company Ariceum Therapeutics has announced the successful completion of Series A extension financing, raising an additional €22.75m following …

Merck acquires Prometheus Biosciences, strengthens immunology pipeline

April 17, 2023 Sales and Marketing

Merck (known as MSD outside of the US and Canada) has announced that it, through a subsidiary, has agreed to …

Neuromod closes €30m financing for new tinnitus treatment device

April 14, 2023 Sales and Marketing

Irish medical device company Neuromod has announced that it has successfully closed a €30m financing intended to further commercialise Lenire, …

Adcendo ApS to Present Data on the Expression of the Novel ADC target uPARAP in Soft Tissue and Bone Sarcoma at the 2023 American Association for Cancer Research (AACR) Annual Meeting

April 13, 2023 Sales and Marketing

Copenhagen, Denmark, 13 April, 2023 – Adcendo ApS (“Adcendo”), a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) …

Alentis Therapeutics closes $105m Series C funding for new treatment options

April 13, 2023 Sales and Marketing

Alentis Therapeutics has announced $105m in Series C funding which was led by Jeito Capital together with Novo Holdings A/S …

ImaginAb signs new license and supply agreement with Leucid Bio for CD8 ImmunoPET technology

April 12, 2023 Sales and Marketing

Biotechnology company ImaginAb has announced that it has signed a new non-exclusive License and Supply Agreement (LSA) with Leucid Bio. …

Latest content